STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

SI-BONE to Present at Morgan Stanley 23rd Global Healthcare Conference on September 9, 2025

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

SI-BONE (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York. The company's management will conduct a fireside chat on September 9, 2025, at 4:00 AM PT / 7:00 AM ET.

Investors can access the presentation through registration, and a live webcast will be available on SI-BONE's investor relations website. The webcast recording will remain accessible for at least 90 days following the event.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction 1 Alert

+1.04% News Effect

On the day this news was published, SIBN gained 1.04%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SANTA CLARA, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY. Management will be hosting a fireside chat on Tuesday, September 9, 2025, at 4:00 a.m. Pacific Time/ 07:00 a.m. Eastern Time.

Investors interested in listening to the conference call may do so by registering at this link: Morgan Stanley 23rd Global Healthcare Conference. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.

About SI-BONE, Inc.

SI-BONE (NASDAQ: SIBN) is a global leader in developing unique technologies for surgical treatment of sacropelvic disorders. Since pioneering minimally invasive SI joint surgery in 2009 with the iFuse Implant System®, SI-BONE has supported over 4,600 physicians in performing a total of nearly 130,000 procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies with over 175 peer reviewed publications including four randomized controlled trials. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic and sacropelvic fixation and pelvic trauma.

For additional information on the company or the products, including risks and benefits, please visit www.si-bone.com.

SI-BONE, Sacropelvic Solutions, iFuse Implant System®, iFuse Bedrock Granite, and iFuse TORQ, are registered trademarks, and iFuse 3D, iFuse TORQ TNT, and iFuse INTRA are trademarks of SI-BONE, Inc. ©2025 SI-BONE, Inc. All Rights Reserved. 

Investor Contact: Saqib Iqbal investors@si-bone.com


FAQ

When is SI-BONE (SIBN) presenting at the Morgan Stanley Healthcare Conference 2025?

SI-BONE will present on Tuesday, September 9, 2025, at 4:00 AM PT / 7:00 AM ET through a fireside chat format.

How can investors access SI-BONE's (SIBN) Morgan Stanley conference presentation?

Investors can access the presentation by registering through the provided link and viewing the live webcast on SI-BONE's website in the 'Investors' section.

How long will SI-BONE's (SIBN) Morgan Stanley conference presentation be available for replay?

The webcast will be archived and available for replay for at least 90 days after the event on SI-BONE's website.

What type of medical devices does SI-BONE (SIBN) specialize in?

SI-BONE is a medical device company that specializes in solving sacropelvic disorders.
Si-Bone

NASDAQ:SIBN

SIBN Rankings

SIBN Latest News

SIBN Latest SEC Filings

SIBN Stock Data

816.62M
39.43M
2.98%
96.62%
5.01%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
SANTA CLARA